Your browser doesn't support javascript.
loading
Dosimetric correlates of toxicities and quality of life following two-fraction stereotactic ablative radiotherapy (SABR) for prostate cancer.
Ong, Wee Loon; Davidson, Melanie; Cheung, Patrick; Chung, Hans; Chu, William; Detsky, Jay; Liu, Stanley; Morton, Gerard; Szumacher, Ewa; Tseng, Chia-Lin; Vesprini, Danny; Ravi, Ananth; McGuffin, Merrylee; Zhang, Liying; Mamedov, Alexandre; Deabreu, Andrea; Kulasingham-Poon, Meghan; Loblaw, Andrew.
Afiliación
  • Ong WL; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Canada; Alfred Health Radiation Oncology, Monash University, Melbourne, Australia.
  • Davidson M; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Canada.
  • Cheung P; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Canada.
  • Chung H; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Canada.
  • Chu W; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Canada.
  • Detsky J; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Canada.
  • Liu S; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Canada.
  • Morton G; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Canada.
  • Szumacher E; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Canada.
  • Tseng CL; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Canada.
  • Vesprini D; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Canada.
  • Ravi A; Department of Radiation Oncology, University of Toronto, Canada; Molli Surgical, Toronto, Canada.
  • McGuffin M; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada.
  • Zhang L; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada.
  • Mamedov A; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada.
  • Deabreu A; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada.
  • Kulasingham-Poon M; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada.
  • Loblaw A; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Canada; Department of Health Policy, Measurement and Evaluation, University of Toronto, Canada. Electronic address: Andrew.Loblaw@sunnybrook.ca.
Radiother Oncol ; 188: 109864, 2023 Nov.
Article en En | MEDLINE | ID: mdl-37619656
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Tipo de estudio: Prognostic_studies / Qualitative_research Idioma: En Revista: Radiother Oncol Año: 2023 Tipo del documento: Article País de afiliación: Australia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Tipo de estudio: Prognostic_studies / Qualitative_research Idioma: En Revista: Radiother Oncol Año: 2023 Tipo del documento: Article País de afiliación: Australia